S‐adenosylmethionine treatment prevents carbon tetrachloride—induced S‐adenosylmethionine synthetase inactivation and attenuates liver injury

Fernando Corrales, América Giménez, Luis Alvarez, Joan Caballería, María A. Pajares, Hernán Andreu, Albert Parés, José M. Mato, Joan Rodés – 1 October 1992 – Administration of carbon tetrachloride to rats resulted in induction of hepatic fibrosis and a 60% reduction of hepatic S‐adenosylmethionine synthetase activity without producing any significant modification of hepatic levels of S‐adenosylmethionine synthetase messenger RNA. The reduction of S‐adenosylmethionine synthetase activity was corrected by treatment with S‐adenosylmethionine (3 mg/kg/day, intramuscularly).

Hepatitis C viral infection in liver transplant recipients

Linda D. Ferrell, Teresa L. Wright, John Roberts, Nancy Ascher, John Lake – 1 October 1992 – In this study we examined multiple serial liver biopsy specimens from liver transplant recipients to determine the pathological features of hepatitis C virus—induced hepatitis. Hepatitis C virus infections acquired after transplantation and previous infections that recurred in patients after transplantation were confirmed by the results of the polymerase chain reaction. Of 43 patients infected with the hepatitis C virus, 18 had a mild form of chronic hepatitis.

Ursodeoxycholic acid therapy in cystic fibrosis—associated liver disease: A dose‐response study

Carla Colombo, Andrea Crosignani, Marisa Assaisso, Pier Maria Battezzati, Mauro Podda, Annamaria Giunta, Linda Zimmer‐Nechemias, Kenneth D. R. Setchell – 1 October 1992 – Previous studies from our groups have demonstrated improvements in biochemical markers of liver function when cystic fibrosis patients with associated liver disease were administered oral ursodeoxycholic acid.

Deficient interleukin‐2 responsiveness of T lymphocytes from patients with primary biliary cirrhosis

José Luis Menéndez, José Antonio Girón, Luis Manzano, Aurelio Garrido, Luis Abreu, Agustin Albillos, Alberto Durántez, Melchor Alvarez‐Mon – 1 October 1992 – There is increasing evidence that primary biliary cirrhosis is associated with an alteration of the immune system. Although the cause remains unknown, it has been suggested that the immune system of patients with primary biliary cirrhosis is involved in the pathogenesis of their disease.

Effect of loxiglumide and atropine on erythromycin‐induced reduction in gallbladder volume in human subjects

Max C. W. Jebbink, Ad A. M. Masclee, Frank G. H. van der Kleij, Jaap Schipper, Lucio C. Rovati, Jan B. M. J. Jansen, Cornelis B. H. W. Lamers – 1 October 1992 – This study was undertaken to investigate the effect of erythromycin, a motilin agonist with prokinetic activity, on fasting gallbladder volume.

The P53 “knockout”: Gone but not forgotten

David Carbone – 1 October 1992 – Mutations in the p53 tumour‐suppressor gene are the most frequently observed genetic lesions in human cancers. To investigate the role of the p53 gene in mammalian development and tumorigenesis, a null mutation was introduced into the gene by homologous recombination in murine embryonic stem cells. Mice homozygous for the null allele appear normal but are prone to the spontaneous development of a variety of neoplasms by 6 months of age.

Subscribe to